The Drug Safety Lifecycle · Section 3.1
~7 min read · The Drug Safety Coach — Global PV Career Course
This module's video isn't published yet
Visit the channel →Key points
PV activities by development phase
| Phase | Duration | Key PV Activities |
|---|---|---|
| Discovery & Preclinical | 2–4 years | Toxicity profiling, ICH M3(R2) & S-series, QSAR/in silico prediction, safety pharmacology |
| Phase I (Human Pharmacology) | 1–2 years | First-in-human dose escalation, SUSAR reporting begins (7/15-day rules), DSMB activated |
| Phase II (Therapeutic Exploration) | 2–3 years | ADR pattern recognition, expedited SUSAR reporting, DSUR preparation begins |
| Phase III (Confirmatory Trials) | 3–5 years | Full safety database compilation, RMP development, benefit-risk documentation |
| Regulatory Review & Approval | 1–2 years | PRAC/FDA safety assessment, RMP finalisation, post-marketing commitments defined |
| Post-Marketing (Lifecycle PV) | Product lifetime | Continuous ICSR collection, signal detection, PBRER/PSUR, PASS/PAES, AI-assisted surveillance |
Full text
Every medicinal product travels a complex journey — from the spark of discovery to decades of vigilant monitoring in the real world. This journey, the Drug Safety Lifecycle, is the continuous process of identifying, evaluating, managing, and preventing risks associated with medicines. Pharmacovigilance does not start when a drug reaches the market — it begins during preclinical development and continues until withdrawal or replacement by a safer alternative.
In the modern era, this lifecycle has evolved from a linear progression — discover, test, approve, monitor — into a cyclical, data-driven system in which safety insights from post-marketing experience feed back into preclinical strategies, clinical design, and regulatory policy for future products. Artificial intelligence has added a fourth operational dimension: adaptivity. PV systems no longer simply collect and report — they learn, predict, and alert.
The development of a medicinal product unfolds across distinct but interconnected phases, each with a primary scientific objective — toxicology characterisation, dose-finding, efficacy confirmation — but each also carrying explicit pharmacovigilance obligations running in parallel. For gene therapies, cell therapies, and ATMPs, the timeline is longer, the safety unknowns greater, and post-marketing follow-up extends across 15 years or more.
What this table makes visible is something easy to lose sight of day-to-day: PV isn’t a function that switches on at launch. A signal-detection specialist reviewing a post-marketing PBRER is, in a real sense, continuing work that a toxicologist started a decade earlier — the same safety story, just at a later chapter.
Note
The total development timeline from discovery to first marketing authorisation typically spans 10–15 years and costs more than USD 1 billion for a novel molecular entity. Pharmacovigilance activities run continuously across this entire period — not as add-ons, but as integrated requirements that shape the development programme’s design, documentation, and regulatory submissions.
Quick check
Test yourself before moving on — no pressure, just click an answer.
1. At which phase does the SUSAR reporting obligation (7/15-day rules) begin?
2. What "fourth dimension" has AI added to the traditional discover-test-approve-monitor lifecycle?